OS Therapies OSTX
NYSE OSTX
$1.65 +0.04 (+2.48%)
As of: Sep 30, 2026 · 10:24 AM EDT

OS Therapies (OSTX) Short term Debt (2023 - 2024)

Updated

OS Therapies (OSTX) posted Short term Debt of $16.45 million for Q2 2024, up 6.4% from the prior quarter.

Analysis

OS Therapies (OSTX) Short term Debt (2023 - 2024) Analysis & Trends

At the end of FY2023, OS Therapies' Short term Debt came in at $14.61 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 OS Therapies 7.83 Mn 7.83 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 16.45 Mn
Mar 31, 2024 15.46 Mn
Dec 31, 2023 14.61 Mn
API Access

OS Therapies Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=OSTX&period=max&api_key=YOUR_API_KEY